Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Screening fecal enterococci from Greek healthy infants for susceptibility to antimicrobial agents.

Kirtzalidou EI, Mitsou EK, Pramateftaki P, Kyriacou A.

Microb Drug Resist. 2012 Dec;18(6):578-85. doi: 10.1089/mdr.2012.0028.

PMID:
22827719
2.
3.

Characterization of functional, safety, and probiotic properties of Enterococcus faecalis UGRA10, a new AS-48-producer strain.

Cebrián R, Baños A, Valdivia E, Pérez-Pulido R, Martínez-Bueno M, Maqueda M.

Food Microbiol. 2012 May;30(1):59-67. doi: 10.1016/j.fm.2011.12.002.

PMID:
22265284
4.

Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation.

Steck N, Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL, Mair K, Krueger D, Pruteanu M, Shanahan F, Vogelmann R, Schemann M, Kuster B, Sartor RB, Haller D.

Gastroenterology. 2011 Sep;141(3):959-71. doi: 10.1053/j.gastro.2011.05.035.

PMID:
21699778
5.

Probiotics have clinical, microbiologic, and immunologic efficacy in acute infectious diarrhea.

Chen CC, Kong MS, Lai MW, Chao HC, Chang KW, Chen SY, Huang YC, Chiu CH, Li WC, Lin PY, Chen CJ, Li TY.

Pediatr Infect Dis J. 2010 Feb;29(2):135-8.

PMID:
20135748
6.

A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome--a randomized controlled trial with primary care physicians.

Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S.

Neurogastroenterol Motil. 2008 Oct;20(10):1103-9. doi: 10.1111/j.1365-2982.2008.01156.x.

7.

Infant intestinal Enterococcus faecalis down-regulates inflammatory responses in human intestinal cell lines.

Wang S, Ng LH, Chow WL, Lee YK.

World J Gastroenterol. 2008 Feb 21;14(7):1067-76.

8.

Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells.

Are A, Aronsson L, Wang S, Greicius G, Lee YK, Gustafsson JA, Pettersson S, Arulampalam V.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1943-8. doi: 10.1073/pnas.0711734105.

9.

Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy.

Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y.

Scand J Gastroenterol. 2007 Nov;42(11):1306-11.

PMID:
17852859
10.
11.

Characterisation of intestinal bacteria in infant stools using real-time PCR and northern hybridisation analyses.

Hopkins MJ, Macfarlane GT, Furrie E, Fite A, Macfarlane S.

FEMS Microbiol Ecol. 2005 Sep 1;54(1):77-85.

12.

Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria.

Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB.

Gastroenterology. 2005 Apr;128(4):891-906.

PMID:
15825073
13.
14.
15.

Streptococcus faecalis, a bacterial isolate which protects young chickens from enteric invasion by Salmonellae.

Soerjadi AS, Lloyd AB, Cumming RB.

Aust Vet J. 1978 Nov;54(11):549-50. No abstract available.

PMID:
111659
16.

Carriage of group D streptococci in the human bowel.

Noble CJ.

J Clin Pathol. 1978 Dec;31(12):1182-6.

Items per page

Supplemental Content

Support Center